Novo Medi Sciences Private Limited

Novo 60mg Enoxaparin Sodium Injection IP is an anticoagulant medication primarily used to prevent and treat deep vein thrombosis (DVT) and pulmonary embolism (PE). It is a low molecular weight heparin (LMWH) that works by inhibiting factors involved in blood clotting, particularly Factor Xa.

Description:

• Active Ingredient: Enoxaparin Sodium
• Strength: 60 mg
• Formulation: Injectable solution, typically pre-filled syringes for subcutaneous administration.
• Indications: Used for the prevention of DVT in patients undergoing surgery or in those with restricted mobility, and for the treatment of existing DVT and PE.
• Administration: Administered subcutaneously as directed by a healthcare provider.
• Storage: Store in a refrigerator; do not freeze.

Important Considerations:

• Monitoring: Regular monitoring of blood parameters may be required, especially in patients with renal impairment.
• Side Effects: Common side effects may include bleeding, injection site reactions, and thrombocytopenia. Patients should be monitored for signs of bleeding.
• Contraindications: Use with caution in patients with a history of heparin-induced thrombocytopenia, active bleeding, or severe renal impairment.

Composition: 
Enoxaparin Sodium

 

Dosage Form:
PFS for Injection

 

Indications:
Acute Coronary syndrome, Deep vein thrombosis treatment, Venous thromboembolism prophylaxis.

 

Novo Enoxaparin Sodium Injection IP is a medication used as an anticoagulant (blood thinner) to prevent and treat various thromboembolic disorders. It is derived from low molecular weight heparin and is typically indicated for conditions such as deep vein thrombosis (DVT), pulmonary embolism, and for the prevention of blood clots in patients undergoing certain surgeries.

Key Features:

• Active Ingredient: Enoxaparin sodium
• Formulation: Injectable solution
• Dosage Forms: Typically available in pre-filled syringes for ease of administration
• Mechanism of Action: Enoxaparin works by inhibiting factor Xa and to a lesser extent factor IIa (thrombin), which helps prevent the formation of blood clots.
• Indications:
  • Treatment and prevention of DVT and pulmonary embolism
  • Prevention of thrombus formation in patients undergoing surgery
  • Management of unstable angina and non-ST elevation myocardial infarction (NSTEMI)

Administration:

• Route: Subcutaneous injection
• Dosage: Varies based on the condition being treated, patient weight, and other factors. It's essential to follow healthcare provider instructions.

Side Effects:

Common side effects may include:

• Bleeding or bruising
• Injection site reactions (pain, redness, swelling)
• Allergic reactions (rare)

Precautions:

• Monitor for signs of bleeding
• Use with caution in patients with renal impairment, active bleeding, or those undergoing spinal procedures

Novo Heparin Sodium Injection IP is an anticoagulant medication primarily used to prevent and treat thromboembolic disorders. It contains heparin sodium, a naturally occurring polysaccharide that inhibits blood clot formation by enhancing the activity of antithrombin III, which inactivates thrombin and factor Xa.

Indications:

• Prophylaxis and treatment of venous thromboembolism (e.g., deep vein thrombosis, pulmonary embolism)
• Prevention of clot formation during certain medical procedures (e.g., dialysis, surgery)
• Management of unstable angina and myocardial infarction

Dosage Forms:

• Typically available as a sterile solution for injection, with varying concentrations.

Administration:

• Administered via subcutaneous or intravenous injection, depending on the clinical scenario.

Precautions:

• Monitor for signs of bleeding or thrombocytopenia.
• Adjust dosage in patients with renal impairment or those at high risk of bleeding.

Side Effects:

• Common side effects may include bleeding, bruising, and pain at the injection site.
• Rarely, it may cause heparin-induced thrombocytopenia (HIT).

Heparin Sodium Injection is an anticoagulant used to prevent and treat blood clots. It acts by inhibiting thrombin and activated factor Xa, thereby preventing the formation and extension of clots.